AstraZeneca to send direct mail for Toprol-XL

Share this article:
AstraZeneca will send out direct-mail communications as part of a larger campaign for its hypertension drug, Toprol-XL, following reports of name confusion between the treatment and other Rx brands. The overall program launch's audience will include pharmacists and pharmacy technicians, physicians, physician assistants, nurse practitioners, nurses and patients.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.